Venom Diversity |
May effectively neutralize a wide range of snake species and venom types due to the use of whole venoms for immunization. |
May struggle to completely neutralize all snake species or venom types due to the specific targeting of venom components or toxins. |
[17,27,42,114] |
Regulatory Approval |
Typically has a more straightforward and well-established regulatory approval process. |
May face a more intricate and time-consuming regulatory approval process, potentially causing delays in availability. |
[40,53,54] |
Stability and Storage |
Generally, has a longer shelf life, more stable storage conditions, and consistent dosing. |
Could require specific stability and storage conditions, potentially having a shorter shelf life, dose variations, and potential renal elimination. |
[77] |
Adverse Reactions |
Can elicit adverse reactions, including anaphylaxis, requiring medical supervision and monitoring. |
Carries the potential for adverse reactions, necessitating thorough medical supervision and monitoring. |
[16,27,81,115] |
Clinical Efficacy and Safety |
Well-established clinical efficacy and safety through extensive use and trials. |
Clinical efficacy and safety may be less comprehensively established, with uncertainty about long-term effectiveness and safety. |
[48,116,117] |
Cost |
Typically ranges from USD 13 to $1120 per treatment. |
Potentially more cost-effective, with estimates of approximately USD 20 to $225 for monovalent and USD 48 to $1354 for polyvalent recombinant antivenoms per treatment. |
[51] |
Scalability |
May be limited by the availability of venom sources and animal immunization. |
Offers potential for large-scale production, providing cost-effective solutions for regions with high snakebite incidents. |
[52,53] |
Production Advancements |
Rely on traditional methods and do not integrate modern biotechnological advances. |
Benefit from modern biotechnological advancements and targeted toxin identification, potentially enhancing efficacy and reducing adverse reactions. |
[35,46,47] |